Evaluation of the effect of flavangenol on serum lipid peroxide levels and development of atherosclerosis in spontaneously hyperlipidemic B6.KOR-Apoe shl mice

International Journal of Molecular Medicine

Volumn 27, Issue 1, 2011, Pages 33-38

  Sugaya, Kouichi ^a   Igarashi, Mamoru ^a   Kojima, Yuko ^a   Tsubata, Masahito ^b   Nagaoka, Isao ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b Toyo Shinyaku Co Ltd   (Japan)

Author keywords

Antioxidant; Atherosclerosis; Hyperlipidemic mice; Lipid peroxide; Pine bark extract

Indexed keywords

ANTIOXIDANT; FLAVANGENOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA INTIMA; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; HYPERLIPIDEMIA; INFLAMMATORY INFILTRATE; LIPID STORAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAINING; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIFLAVONOIDS; HUMANS; HYPERLIPIDEMIAS; LIPID PEROXIDES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLANT EXTRACTS; PROANTHOCYANIDINS;

EID: 78651063745     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2010.554     Document Type: Article

References (24)

1. Breslow JL: Cardiovascular disease burden increases, NIH funding decreases. Nat Med 3: 600-601, 1997.
2. Li H, Witte K, August M, Brausch I, Armbrust U, Habermeier A, Closs EI, Oelze M, Munzel T and Forstermann U: Reversal of eNOS uncoupling and upregulation of eNOS expression lowers blood pressure in hypertensive rats. J Am Coll Cardiol 47: 2536-2544, 2006.
3. Hink U, Li H, Mollnau H, Olze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U and Munzel T: Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88: e14-e22, 2001.
4. Burke A and Fitzgerald GA: Oxidative stress and smoking-induced vascular injury. Prog Cardiovasc Dis 46: 79-90, 2003.
5. Whitman SC: A practical approach to using mice in atherosclerosis research. Clin Biochem Rev 25: 81-93, 2004.
6. Packer L, Rimbach G and Virgili F: Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus Maritima) bark, pycnogenol. Free Radic Biol Med 27: 704-724, 1999.
7. Nelson AB, Lau BH, Ide N and Rong Y: Pycnogenol inhibits macrophage oxidative burst, lipoprotein oxidation, and hydroxyl radical-induced DNA damage. Drug Dev Ind Pharm 24: 139-144, 1998. (Pubitemid 28085152)
8. Golanski J, Muchova J, Golanki R, Durackova Z, Markuszewski L and Watara C: Does pycnogenol intensify the efficacy of acetylsalicylic acid in the inhibition of platelet function? In vitro experience. Postepy Hig Med Dosw 60: 316-321, 2006.
9. Fitzpatrrick DF, Bing B and Rohdewald P: Endothelium-dependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol 32: 509-515, 1998.
10. Sato M, Yamada Y, Matsuoka H, Nakashima S, Kamiya T, Ikeguchi M and Imaizumi K: Dietary pine bark extract reduces atherosclerotic lesion development in male ApoE-deficient mice by lowering the serum cholesterol level. Biosci Biotechnol Biochem 73: 1314-1314, 2009.
11. Auclair A, Milenkovic D, Besson C, Chuvet C, Gueux E, Morand C, Mazur A and Scalbert A: Catechin reduced atherosclerotic lesion development in apo E-deficient mice: a transcriptomic study. Atherosclerosis 204: e21-e27, 2009.
12. Miyazaki K, Makino K, Iwata E, Deguchi Y and Ishikawa F: Anthocyanins from purple sweet potato lpomoea batatas cultivar Ayamurasaki suppress the development of atherosclerotic lesions and both enhancements of oxidative stress and soluble vascular cell adhesion molecule-1 in apolipoprotein E-deficient mice. J Agric Food Chem 56: 11485-11492, 2008.
13. Catapano AL: Antioxidant effect of flavonoids. Angiology 48: 39-44, 1997.
14. Hertog MGL, Feskens EJM and Kromhout D: Antioxidant flavonols and coronary heart disease risk. Lancet 349: 699, 1997.
15. Putter M, Grotemeyer KH, Wurthwein G, Aragi-Niknam M, Watson RR, Hosseini S and Rohdewald P: Inhibition of smoking-induced platelet aggregation by aspirin and pycnogenol. Thromb Res 95: 155-161, 1999.
16. Matushima Y, Sakurai T, Ohnuki T, Tada N, Asoh Y and Tachibana M: Four strains of spontaneously hyperlipidemic (SHL) mice: phenotypic distinctions determined by genetic backgrounds. J Atheroscler Thromb 8: 71-79, 2001.
17. Matushima Y, Hayashi S and Tachibana M: Spontaneously hyperlipidemic (SHL) mice: Japanese wild mice with apolipoprotein E deficiency. Mamm Genome 10: 352-357, 1999.
18. Fearon IM and Faux SP: Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J Mol Cell Cardiol 47: 372-381, 2009.
19. Rader DJ and Daugherty A: Translating molecular discoveries into new therapies for atherosclerosis. Nature 415: 904-913, 2008.
20. Cathcart MK: Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler Thromb Vasc Biol 24: 23-28, 2004. (Pubitemid 38082407)
21. Ferdinand KC: The importance of aggressive lipid management in patients at risk: evidence from recent clinical trials. Clin Cardiol 27: 12-15, 2004
22. Bittner V: Perspectives on dyslipidemia and coronary heart disease in women. J Cardiol 46: 1628-1638, 2005.
23. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S and Tyroler HA: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79: 8-15, 1989.
24. Jan M, Meng S, Chen NC, Mai J, Wang H and Yang XF: Inflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics. J Biomed Biotechnol 2010: 459798, 2010.